ATOS 8-K
Atossa Therapeutics, Inc. (ATOS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: ( |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 8, 2025, Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on March 20, 2025, the record date for the Annual Meeting, there were 129,170,004 shares of common stock, par value $0.18 per share, entitled to vote at the meeting.
At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the majority of votes cast on Proposal 4 and each of the other proposals voted on was approved. The final voting results are set forth below.
The stockholders elected the two Class I directors by the following votes:
Nominee |
Votes |
Votes |
Broker Non-Votes |
• Steven C. Quay, M.D., Ph.D. |
28,401,118 |
4,195,118 |
31,334,563 |
• Jonathan F. Finn, C.F.A. |
30,196,246 |
2,399,990 |
31,334,563 |
The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 by the following votes:
Votes |
Votes |
Abstentions |
Broker Non-Votes |
55,807,388 |
6,678,230 |
1,445,181 |
0 |
The stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers by the following votes:
Votes |
Votes |
Abstentions |
Broker Non-Votes |
25,638,054 |
6,479,149 |
479,033 |
31,334,563 |
The stockholders approved, on a non-binding, advisory basis, a frequency of one year on future advisory votes on the compensation of the Company’s named executive officers by the following votes:
1 Year |
|
3 Years |
Abstentions |
Broker Non-Votes |
29,326,201
|
950,899 |
1,818,942 |
500,194 |
31,334,563 |
In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Atossa Therapeutics, Inc. |
|
|
|
|
Date: |
May 9, 2025 |
By: |
/s/ Heather Rees |
|
|
|
Heather Rees |